Clinical Trial Update: Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating parsaclisib in combination with CHOP for previously untreated peripheral T-cell lymphoma is ongoing, with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Parsaclisib (parsaclisib)

Snippet

Sponsor: Fudan University | Conditions: PI3Kδ Inhibitor, Parsaclisib | Phase 1, Phase 2 | Status: UNKNOWN